Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8222520 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL3669860 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL14191224 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL8320089 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL13646429 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL8037005 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL13630595 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL3793643 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL3793642 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL11894637 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805726-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9493506-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9309279-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150119319-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2015-04-30 | — | — | US | disclosed |
| US-8951964-B2 | Phenanthridine macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8937041-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| EP-2805726-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2468285-B1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140287992-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBOTT LABORATORIES | 2014-09-25 | — | — | US | disclosed |
| US-8748374-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120172291-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-07-05 | — | — | US | disclosed |
| WO-2012092409-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARARMACEUTICALS, INC (US) | 2012-07-05 | — | — | WO | disclosed |
| EP-2468286-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2468285-A1 | Macrocyclic hepatitis C serine protease inhibitors | Enanta Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2011156337-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | WO | disclosed |
| EP-2340029-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20100168384-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. | 2010-06-10 | — | — | US | disclosed |
| WO-2010030359-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARJMACEUTICALS, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101031-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | ADRB3 3933/4885ADRA2B 4558/4885ADRA2C 3776/4885 |
| US-20150119319-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | ADRB3 3516/4885ADRA2B 4329/4885ADRA2C 3375/4885 |
| US-20120172291-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | ADRB3 3516/4885ADRA2B 4329/4885ADRA2C 3375/4885 |
| US-20100168384-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ADRB3 4133/4885ADRA2B 4599/4885ADRA2C 4221/4885 |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | TMPRSS15, PRSS1, SPINT2 | ADRB3 3933/4885ADRA2B 4558/4885ADRA2C 3776/4885 |
| US-20140287992-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | ADRB3 3933/4885ADRA2B 4558/4885ADRA2C 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.